Research programme: cardiovascular disease gene/cell therapies - Anges/Tokyo Hospital

Drug Profile

Research programme: cardiovascular disease gene/cell therapies - Anges/Tokyo Hospital

Latest Information Update: 05 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnGes MG; University of Tokyo
  • Class Cell therapies; Gene therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cardiovascular disorders

Most Recent Events

  • 30 Aug 2005 This programme is still in active development
  • 01 Feb 2005 Preclinical trials in Cardiovascular disorders in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top